Converting intravenous dosing to subcutaneous dosing: With recombinant human hyaluronidase

Pharmaceutical Technology

Volumn 31, Issue 10, 2007, Pages 118-132

  Haller, Michael F ^a  

^a Halozyme Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACIDS; AGENTS; BIOCHEMISTRY; DNA; DRUG DELIVERY; ENZYMES; GENETIC ENGINEERING; NUCLEIC ACIDS; TISSUE;

CLINICAL DEVELOPMENT; DRUG DELIVERY SYSTEM; EXTRA CELLULAR MATRICES; GENE FAMILIES; HYALURONIC ACID; MOLECULAR ENGINEERING; RECOMBINANT DNA; TRANSIENT DEGRADATION;

ORGANIC ACIDS;

HYALURONIC ACID; HYALURONIDASE; INFLIXIMAB; PEGINTERFERON ALPHA2B; PROTEIN; RECOMBINANT ENZYME; RECOMBINANT HYALURONIDASE; UNCLASSIFIED DRUG;

DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; EXTRACELLULAR MATRIX; NONHUMAN; PROTEIN ENGINEERING; RECOMBINANT DNA TECHNOLOGY; REVIEW;

EID: 53649107735     PISSN: 15432521     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. D. Gilbert and & D. Cothran, "SC versus IV Delivery: Reducing Costs while Increasing Patient Satisfaction," Hematology & Oncology News & Issues, Dec. 25-27, 2005.
2. J. Prettyman, "Subcutaneous or Intramuscular? Confronting a Parenteral Administration Dilemma," Medsurg. Nursing, 14 (2), 93-98 (2005).
3. H.C. Ansel, L.V. Allen, and N.G. Popovich, Pharmaceutical Dosage Forms and Drug Delivery Systems (Lippincott Williams & Wilkins, Philadelphia, PA, 8th ed., 2004).
4. A.L. Alcantara et al., "Radiologic Study of Injection Drug Use Complications," Infect. Dis. Clin. North Am. 16 (3), 713-743 (2002).
5. P.D. Brown and J.R. Ebright, "Skin and Soft Tissue Infections in Injection Drug Users," Curr. Infect. Dis. Rep. 4 (5), 415-419 (2002).
6. S. Satyanarayana and A.D. Mathur, "Atypical Mycobacterial Injection Abscess," J. Indian Med. Assoc. 101 (1), 36-40 (2003).
7. S.C. DeWitt, Fundamental Concepts and Skills for Nursing (WB Saunders Company, Philadelphia, PA, 2001).
8. P.S. Bergeson, S.A. Singer, and A.M. Kaplan, "Intramuscular Injections in Children," Pediatrics 70 (6), 944-948 (1982).
9. A. Supersaxo, W.R. Hein, and H. Steffen, "Effect of Molecular Weight on the Lymphatic Absorption of Water-soluble Compounds Following Subcutaneous Administration," Pharm. Res. 7 (2), 167-179 (1990).
10. Campath (alemtuzumab) Package Insert, Bayer Healthcare Pharmaceuticals, Wayne, NJ, Jan. 2007.
11. M.C. Hochberg et al., "Comparison of the Efficacy of the Tumor Necrosis Factor α-Blocking Agents Adalimumab, Etanercept, and Infliximab When Added to Methotrexate in Patients with Active Rheumatoid Arthritis," Ann. Rheum. Dis. 62 (suppl 2), ii13-ii16 (2003).
12. E. Nemser and D. Azad, "Assessing the Impact of Differential Reimbursement of Medicare Pharmacy Benefits," Biotechnology Healthcare, Aug. 47-51 (2005).
13. T.D. Day, "The Permeability of Extracellular Connective Tissue and the Nature of the Interfibrillary Substance," J. Physiol. 117 (1), 1-8 (1952).
14. A.H. Paes, A. Bakker, and C.J. Soe-Agnie, "Impact of Dosage Frequency on Patient Compliance," Diabetes Care 20 (10), 1512-1517 (1997).
15. G.I Frost, "Recombinant Human Hyaluronidase (rHuPH20): An Enabling Platform for Subcutaneous and Fluid Administration," Expert Opin. Drug. Del. 4 (4), 427-440 (2007).
16. N. Verzijl et al., "Effect of Collagen Turnover on the Accumulation of Advanced Glycation End Products," J. Biol. Chem. 15 (50), 39027-39031 (2000).
17. U.B.G. Laurent, L.B. Dahl, and P.K. Reed, "Catabolism of Hyaluronan in Rabbit Skin Takes Place Locally in Lymph Nodes and Liver," Exp. Physiol. 76 (5), 695-703 (1991).
18. F. Duran Reynals, "Exaltation de l'Activité du Virus Vaccinal Par les Extraits de Certains Organes," Comptes Rendus Hebdomadaires de Séances et Mémoires de la Société de Biologie. 99, 6-7 (1928).
19. A. Claude and F. Duran-Reynals, "Chemical Properties of the Non-purified Spreading Factor from Testicle," J Exp Med. 65 (5), 661-670 (1937).
20. F. Duran-Reynals, "A Spreading Factor in Certain Snake Venoms and its Relation to their Mode of Action," J. Exp. Med. 69 (1), 69-81 (1939).
21. K. Meyer, "Hyaluronidases," in: The Enzymes, P.D. Boyer Ed., (Academic Press, New York, NY, 3rd edition, 1971), pp. 307-320.
22. K. Meyer, P. Hoffman, and A. Linker, "Hyaluronidases," in The Enzymes, P.D. Boyer, H. Lardy, and K. Myrback, Eds. (Academic Press, New York, NY, 2nd ed., 1960), pp.447-460.
23. R.G. Williams, "The Effects of Continuous Local Injection of Hyaluronidase on Skin and Subcutaneous Tissue in Rats," Anat. Rec. 122 (3), 349-361 (1955).
24. K. Pillwein et al., "Hyaluronidase Additional to Standard Chemotherapy Improves Outcome for Children with Malignant Brain Tumors," Cancer Lett. 131 (1), 101-108 (1998).
25. A.H. Eberhart, C.R. Weiler, and J.C. Erie, "Angioedema Related to the Use of Hyaluronidase in Cataract Surgery," Am. J. Ophthalmol. 138 (1), 142-143 (2004).
26. R.A. Harrison and S.J. Gaunt, "Multiple Forms of Ram and Bull Sperm Hyaluronidase Revealed by Using Monoclonal Antibodies," J. Reprod. Fertil. 82 (2), 777-785 (1988).
27. R.A. Harrison, "Hyaluronidase in Ram serum. Quantitative Determination and Isolation of Multiple Forms," Biochem J. 252 (3), 865-874 (1988).
28. H. Tint and R. Bogash (American Home Products), "Hyaluronidase, " US Patent 2676139, Sept. 1, 1950.
29. H.E. Alburn et al. (American Home Products), "Stabilized Hyaluronidase Solution Containing Calcium Chloride, US Patent 2795529, June 11, 1957.
30. C.L. Borders and M.A. Raftery, "Purification and Partial Characterization of Testicular Hyaluronidase," J. Biol. Chem. 243 (13), 3756-3762 (1968).
31. W.F. Lathrop et al., "cDNA Cloning Reveals the Molecular Structure of a Sperm Surface Protein, PH-20, Involved in Sperm-egg Adhesion and the Wide Distribution of its Gene among Mammals," J. Cell. Biol. 111 (6 Pt 2), 2939-2949 (1990).
32. M. Gmachl and G. Kreil, "Bee Venom Hyaluronidase is Homologous to a Membrane Protein of Mammalian Sperm," Proc. Natl. Acad. Sci. USA 90 (8), 3569-3573 (1993).
33. A.B. Csoka, G.I. Frost, and R. Stern, "The Six Hyaluronidase-like Genes in the Human and Mouse Genomes," Matrix Biol. 20 (8), 499-508 (2001).
34. Y. Lin et al., "A Hyaluronidase Activity of the Sperm Plasma Membrane Protein PH-20 Enables Sperm to Penetrate the Cumulus Cell Layer Surrounding the Egg," J. Cell. Biol. 125 (5), 1157-1163 (1994).
35. G.N. Cherr et al., "The PH-20 Protein in Cynomolgus Macaque Spermatozoa: Identification of Two Different Forms Exhibiting Hyaluronidase Activity," Dev. Biol. 175 (1), 142-153 (1996).
36. P. Gacesa, N.D. Civill, and R.A. Harrison, "PH-20 and Sperm Hyaluronidase: A Conceptual Conundrum in Mammalian Fertilization," Biochem. J. 303 (Pt. 1), 335-336 (1994).
37. G.I. Frost and R. Stern, "A Microtiter-based Assay for Hyaluronidase Activity not Requiring Specialized Reagents," Anal. Biochem. 251 (2), 263-269 (1997).
38. L.H. Bookbinder et al., "A Recombinant Human Enzyme for Enhanced Interstitial Transport of Therapeutics," J. Control Release 114 (2), 230-241 (2006).
39. H.D. Keiser and V.B. Hatcher, "The Effect of Contaminant Proteases in Testicular Hyaluronidase Preparations on the Immunologic Properties of Bovine Nasal Cartilage Proteoglycan," Connect Tissue Res. 6 (4), 229-233 (1979).
40. V.M. Doctor, H. Spence, and E.Y. Carroll, "Isolation and Properties of a New Anticoagulant Protein from Commercial Bovine Testicular Hyaluronidase," Thromb. Res. 30 (6), 565-571 (1983).
41. M. Hyuga, R. Kodama, and G. Eguchi, "Basic Fibroblast Growth Factor as One of the Essential Factors Regulating Lens Transdifferentiation of Pigmented Epithelial Cells," Int. J. Dev. Biol. 37 (2), 319-326 (1993).
42. J.C. Houck and C.M. Chang, "Permeability Factor Contaminating Hyaluronidase Preparations," Inflammation 3 (4), 447-451 (1979).
43. M. Oettl et al., "Comparative Characterization of Bovine Testicular Hyaluronidase and a Hyaluronate Lyase from Streptococcus agalactiae in Pharmaceutical Preparations," Eur. J. Pharm. 18 (3-4), 267-277 (2003).
44. M.F. Haller et al., "Escaping the Interstitial Matrix with Enzyme-Mediated Drug Delivery," Drug Delivery Technol. 5 (5), 40-45 (2005).